NASDAQ: SABS - SAB Biotherapeutics, Inc.

Доходность за полгода: -45.19%
Дивидендная доходность: 0.00%
Сектор: Healthcare

График акции SAB Biotherapeutics, Inc.


О компании SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

подробнее
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

IPO date 2021-02-09
ISIN US78397T1034
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sabbiotherapeutics.com
Цена ао 1.53
Изменение цены за день: -4.52% (1.55)
Изменение цены за неделю: -13.95% (1.72)
Изменение цены за месяц: -15.43% (1.75)
Изменение цены за 3 месяца: -64.59% (4.18)
Изменение цены за полгода: -45.19% (2.7)
Изменение цены за год: -67.4% (4.54)
Изменение цены за 3 года: -27.45% (2.04)
Изменение цены с начала года: -62.63% (3.96)

Недооценка

Название Значение Оценка
P/S 1.75 8
P/BV 0.0684 10
P/E 0 0
EV/EBITDA 1.36 10
Итого: 6

Эффективность

Название Значение Оценка
ROA, % -50.27 0
ROE, % -73.64 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого: 0

Долг

Название Значение Оценка
Debt/EBITDA -0.1721 10
Итого: 9.6

Импульс роста

Название Значение Оценка
Доходность Revenue, % -34.15 0
Доходность Ebitda, % 365.04 10
Доходность EPS, % 3428.04 10
Итого: 8

Институционалы Объем Доля, %
Marshall Wace LLP 4585282 49.7
RA Capital Management, L.P. 2374081 25.73
COMMODORE CAPITAL LP 1831746 19.86
RTW Investments LP 917828 9.95
BVF Inc. 917828 9.95
Sessa Capital IM, L.P. 458457 4.97
Vanguard Group Inc 99614 1.08
First Premier Bank 80754 0.88
Pathstone Holdings, LLC 50651 0.55
Geode Capital Management, LLC 35636 0.39



Руководитель Должность Оплата Год рождения
Mr. Samuel J. Reich CEO & Executive Chairman 363.2k 1975 (50 лет)
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 402.56k 1966 (59 лет)
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 25k 1956 (69 лет)
Dr. Alexandra Kropotova M.B.A., M.D. Executive VP & Chief Medical Officer 774.45k 1973 (52 года)
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer N/A
Dr. Christoph Bausch M.B.A., Ph.D. Executive VP & COO 443.2k 1971 (54 года)
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Mark W. Conley Interim Chief Financial Officer

Адрес: United States, Sioux Falls. SD, 2100 East 54th Street North - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.sabbiotherapeutics.com